Stem Cell Therapy in Utero Shows Promise for Spina Bifida Treatment
A groundbreaking trial in the United States has demonstrated that administering stem cells to unborn babies diagnosed with spina bifida during in utero surgery could represent a significant advancement in the treatment of birth defects. The experimental therapy, which involves applying stem cells derived from the mother's placenta to the baby's spine while it is being repaired, has been found to be safe and to improve the child's mobility and overall quality of life.
Key Findings from the Trial
The study, published in the Lancet, took place in 2021 and 2022 and focused on six unborn babies with myelomeningocele, the more severe form of spina bifida. Surgeons at the Davis School of Medicine at the University of California applied placenta-derived mesenchymal stem cells to the exposed spinal cords of these babies, who were at 24 to 25 weeks of gestation. Post-birth MRI scans confirmed that hindbrain herniation, a brain abnormality associated with spina bifida, was reversed in all six cases.
Importantly, the stem cells did not lead to tumours, interfere with wound healing, or prevent the reversal of hindbrain herniation, addressing potential side-effects that researchers had anticipated. Dr Diana Farmer, who led the study, described the results as "super exciting" and suggested that this therapy could become the standard of care for spina bifida if it enables more children to walk who otherwise would not.
Expert Reactions and Future Implications
Kate Steele, chief executive of the charity Shine, expressed enthusiasm about the findings, noting that the advances in stem cell science are remarkable and that the safety of the procedure has been demonstrated. She highlighted that improvements in bladder and bowel function would be particularly welcome for those affected by spina bifida.
In a linked comment piece in the Lancet, Dr Magdalena Sanz Cortes, a foetal medicine expert in Texas, stated that if further studies confirm these benefits, it could herald a new era in foetal surgery and potentially reverse neurological damage seen in utero for spina bifida. This trial paves the way for potential new treatments not only for spina bifida but also for other birth defects.
Context and Statistics
It is estimated that between 8,100 and 11,900 people in England and Wales live with open spina bifida, with Shine reporting approximately 536 pregnancies involving the condition each year. The trial's success offers hope for improving outcomes and quality of life for individuals affected by this condition, marking a potential major milestone in medical research and treatment strategies.
